Xylometazoline
Xylometazoline is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target alpha-1D adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| otorhinolaryngologic diseases | D010038 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| metarivin soln. 0.1% | unapproved drug other | 2022-09-30 |
| sinosil | OTC monograph final | 2011-02-09 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AA: Sympathomimetics, plain
— R01AA07: Xylometazoline
— R01AB: Sympathomimetics, combinations excl. corticosteroids
— R01AB06: Xylometazoline
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01G: Decongestants and antiallergics
— S01GA: Sympathomimetics used as decongestants
— S01GA03: Xylometazoline
— S01GA53: Xylometazoline, combinations
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Nasal obstruction | D015508 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Xylometazoline |
| INN | xylometazoline |
| Description | Xylometazoline is an alkylbenzene. |
| Classification | Small molecule |
| Drug class | antihistamines/local vasoconstrictors (antazoline type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1 |
Identifiers
| PDB | — |
| CAS-ID | 526-36-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL312448 |
| ChEBI ID | 10082 |
| PubChem CID | 5709 |
| DrugBank | DB06694 |
| UNII ID | WPY40FTH8K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1D
Gene synonyms
ADRA1A
NCBI Gene ID
Protein name
alpha-1D adrenergic receptor
Protein synonyms
adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a
Uniprot ID
Mouse ortholog
Adra1d (11550)
alpha-1D adrenergic receptor (Q61619)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 909 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
679 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use